Plain-English translation of NCT07633587 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
ATROPOS is a research study that looks at medical records from cancer patients worldwide who developed heart inflammation (myocarditis) while being treated with immune checkpoint inhibitors—drugs that help the immune system fight cancer. The study is examining which treatment approaches help patients survive best when this heart inflammation occurs, and what patient factors might predict who is at higher risk.
Heart inflammation can be a serious side effect of immune checkpoint inhibitor therapy, and doctors need better information about which treatment strategies work best to protect patients' hearts and improve survival. This study will help guide doctors in choosing the safest and most effective care for future patients who experience this complication.
You likely qualify if…
You likely don't qualify if…
This is not an active treatment study—you are not assigned to take any new medications or undergo any new procedures. Instead, researchers will review your existing medical records from your cancer care, including information about your heart inflammation, test results, treatments you received, and health outcomes over time. There are no study visits or additional tests required; the study simply analyzes data already collected during your cancer treatment.
AI-generated summary from trial data · Aug 6, 2026 · Not medical advice
France
Sponsor
Groupe Hospitalier Pitie-Salpetriere
Collaborators
Vanderbilt University Medical Center
Enrollment target
~1,500 participants
Started
May 2026
Primary completion
October 2027
Last updated on clinicaltrials.gov in June 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Joe-Elie Salem, MD-PhD
Groupe Hospitalier Pitie-Salpetriere
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.